Gastroenterology Learning Network

Dr Gil Melmed from Cedars-Sinai talks with Drs Raymond Cross and Millie Long about the importance of vaccines, cancer screenings, and other aspects of overall health maintenance for patients with inflammatory bowel disease.

IBD Drive Time: Christina Ha, MD, on Biosimilars by Gastroenterology Learning Network

Guest Christina Ha, MD, from the Mayo Clinic in Arizona, reviews key points about the advent of biosimilars, including reassuring patients and countering the "nocebo" effect, with hosts Drs Raymond Cross and Millie Long.

Experts in gastrointestinal disorders discuss their recently co-authored joint guideline on the pharmacological management of chronic constipation. The podcast explores the collaboration between leading gastrointestinal societies, the 10 recommendations made by the panel, the use of Lube Prostone for treating chronic constipation, the efficacy and dosing instructions of NACLA-TIDE and GCC agonists, and the importance of personalized management approaches.

In part 2 of their podcast on Helicobacter pylori, Drs William Chey and Brian Lacy talk about the risks of untreated disease and the various types of treatment available.

In this first of a two-part podcast on Helicobacter pylori, Drs Brian Lacy and William Chey discuss the prevalence of H pylori infection and how to best diagnose the condition.

Dr David Rubin discusses the obstacles in obtaining IBD therapies. Challenges include affordability, copay accumulators, and delays in prior authorization. Creative solutions like financial assistance and patient assistance programs are key. Advocacy efforts from state and national entities are needed to improve access to care.

Dr Gideon Hirschfield, expert in researching new drugs for PBC, discusses the potential of medications like seladelpar for treating primary biliary cholangitis. Highlights include improved liver tests and symptom relief using celinidelpar, the administration and goals of oral therapy for PBC, the safety and benefits of cello del par, and the positive impact of a new drug on relieving symptoms like itchiness.

This podcast explores the potential of new drugs, including seladelpar, for the treatment of primary biliary cholangitis (PBC). It discusses the effectiveness of seladelpar in improving liver tests, serum biochemistry, and symptom relief. The podcast also highlights the benefits of seladelpar in preventing cirrhosis and improving quality of life in PBC patients. Additionally, it addresses the safety of seladelpar and its potential in addressing symptoms such as itching, fatigue, and abdominal discomfort.

Discussion of clinical trials for inflammatory bowel disease, combination therapy and withdrawal strategies, treatment options for inflammation, IV reintroduction and subcutaneous infliximab for Crohn's disease, and the evaluation of subcutaneous infusions as an alternative treatment option.